Cost-effectiveness of 12- and 15-year-old girls’ human papillomavirus 16/18 population-based vaccination programmes in Lithuania

Abstract

Background: There is a large difference in the prevalence of cervical cancer between European countries. Between European Union countries, cervical cancer is the most prevalent in Lithuania. Currently we have available vaccines for different types of human papillomavirus virus (HPV), but we lack evidence on how the vaccination would be cost-effective in low-resource Eastern European countries like Lithuania. Objectives: To create a simulation model for the Lithuanian population; to estimate epidemiological benefits and cost-effectiveness for a HPV16/18 vaccination programme in Lithuania. Study design: For the cost-effectiveness analysis, we used Lithuanian population mathematical simulation and epidemiological data modelling. We performed comparative analysis of annual vaccination programmes of 12-year-old or 15-year-old girls at different vaccine penetration levels. Population: Lithuanian female population at all age groups. Results: A vaccination programme in Lithuania would gain an average of 35.6 life years per death avoided. Vaccinated girls would experience up to 76.9% overall reduction in incidence of cervical cancers, 80.8% reduction in morbidity and 77.9% reduction in mortality over their lifetime. Cost per life year gained with different vaccine penetration levels would range from 2167.41 to 2999.74. Conclusions: HPV vaccination in Lithuania would have a very positive impact on the epidemiological situation and it would be cost-effective at all ranges of vaccine penetration. Vaccination in Lithuania in the long term potentially could be more cost-effective due to avoiding early disease onset and lower accumulation of period costs.

Keywords

Cervical cancer cost-effectiveness Lithuania mathematical simulation vaccination

Get full access to this article

View all access options for this article.

References

Parkin DM , Bray F. , Ferlay J. , Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005;55(2):74-108.

Parkin DM , Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006;24(Suppl 3):S11-25.

Sanders GD , Taira AV Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003;9(1):37-48.

Clifford G. , Franceschi S. , Diaz M. , Munoz N. , and Villa LL Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006;24 (Suppl 3):S26-34.

Pretet JL , Jacquard AC , Carcopino X. , Monnier-Benoit S. , Averous G. , Soubeyrand B. , et al. Human papillomavirus genotype distribution in high grade cervical lesions (CIN 2/3) in France: EDITH study. Int J Cancer 2008;122(2):424-7.

Walboomers JM , Jacobs MV , Manos MM , Bosch FX , Kummer JA , Shah KV , et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189(1):12-19.

Saranath D. , Khan Z. , Tandle AT , Dedhia P. , Sharma B. , Contractor R. , et al. HPV16/18 prevalence in cervical lesions/ cancers and p53 genotypes in cervical cancer patients from India. Gynecol Oncol 2002;86(2):157-62.

Insinga RP , Dasbach EJ , Elbasha EH , Liaw KL , Barr E. Incidence and duration of cervical human papillomavirus 6. 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives. Cancer Epidemiol Biomarkers Prev 2007;16(4):709-15.

Koutsky LA , Harper DM Chapter 13: Current findings from prophylactic HPV vaccine trials. Vaccine 2006;24 (Suppl 3):S114-21.

10.

Mao C. , Koutsky LA , Ault KA , Wheeler CM , Brown DR , Wiley DJ , et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006;107(1):18-27.

11.

Ault KA Long-term efficacy of human papillomavirus vaccination. Gynecol Oncol 2007;107(2 Suppl):S27-30.

12.

Dasbach EJ , Elbasha EH , Insinga RP Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 2006;28:88-100.

13.

Elbasha EH , Dasbach EJ , Insinga RP Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007;13(1):28-41.

14.

Coupe VM , van Ginkel J. , de Melker HE , Snijders PJ , Meijer CJ , Berkhof J. HPV16/18 vaccination to prevent cervical cancer in The Netherlands: model-based cost-effectiveness. Int J Cancer 2009;124(4):970-8.

15.

Goldie SJ , O’Shea M. , Diaz M. , Kim SY Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications. Reprod Health Matters 2008;16(32):86-96.

16.

Harper DM , Franco EL , Wheeler C. , Ferris DG , Jenkins D. , Schuind A. , et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364(9447):1757-65.

17.

Harper DM , Franco EL , Wheeler CM , Moscicki AB , Romanowski B. , Roteli-Martins CM , et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial . Lancet 2006;367(9518): 1247-55.

18.

Paavonen J. , Jenkins D. , Bosch FX , Naud P. , Salmeron J. , Wheeler CM , et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind. randomised controlled trial. Lancet 2007;369(9580):2161-70.

19.

Hughes JP , Garnett GP , Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 2002;13(6):631-9.

20.

Stanley M. Prophylactic HPV vaccines: prospects for eliminating ano-genital cancer. Br J Cancer 2007;96(9):1320-3.

21.

French KM , Barnabas RV , Lehtinen M. , Kontula O. , Pukkala E. , Dillner J. , et al. Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland. Br J Cancer 2007;96(3):514-18.

22.

Juday T. , Pandya A. , Iskandar R. , Kruzikas D. , Thompson D. , Weinstein M. Cost-effectiveness of vaccination strategies to prevent human papillomavirus infection in the United States. Abstract in Academy of Managed Care Pharmacy’s Educational Conference, 4-6 October 2006, Chicago, USA. 2006.

23.

Taira AV , Neukermans CP , Sanders GD Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004;10(11):1915-23.

24.

Garnett GP Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 2005;191(Suppl 1):S97-106.

25.

Lewsey JD , Leyland AH , Murray GD , Boddy FA Using routine data to complement and enhance the results of randomised controlled trials. Health Technol Assess 2000;4(22):1-55.

26.

Birnbaum HG , Cremieux PY , Greenberg PE , LeLorier J. , Ostrander JA , Venditti L. Using healthcare claims data for outcomes research and pharmacoeconomic analyses. Pharmacoeconomics 1999;16(1):1-8.

27.

Vanagas G. , Padaiga Z. , Bagdonas E. Cost-utility analysis of methadone maintenance treatment: a methodological approach. Subst Use Misuse 2006;41(1):87-101.

28.

Drummond MF , O’Brien B. , Stoddart GL , Torrance GW Methods for the economic evaluation of health care programmes, 2nd edn. Oxford: Oxford University Press; 1997.

29.

Goldhaber-Fiebert JD , Stout NK , Ortendahl J. , Kuntz KM , Goldie SJ , Salomon JA Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metr 2007;5(1):11.

30.

Weinstein MC , Toy EL , Sandberg EA , Neumann PJ , Evans JS , Kuntz KM , et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health 2001;4(5):348-61.